Milnacipran Hydrochloride API

Name	Milnacipran Hydrochloride
Chinese name	盐酸米那普仑
Cas Number	101152-94-7
Source	India
Qualifications	USDMF/-/-/-/-

The development company of milnacipran hydrochloride was PierreFabre, which was first listed in France in 1996, was approved in the United States in 2009 for a new indication for fibromyalgia syndrome, and was listed in China in 2010. Milnacipran hydrochloride is a new type of antidepressant that acts on SERT and NET. It is the only selective serotonin reuptake inhibitor (SNRIs) drug whose NET effect is greater than that of SERT. Its antidepressant effect is stronger. Compared with the currently commonly used tricyclic antidepressants, milnacipran hydrochloride has no affinity for α-adrenergic receptors, muscarinic receptors or H1 histamine receptors, and is not like tricyclic antidepressants It causes orthostatic hypotension, dry mouth, constipation, blurred vision, etc. In addition, milnacipran hydrochloride has the characteristics of good tolerance and low adverse reaction rate. From 2013 to 2018, my country's antidepressant market sales increased from 4.1 billion yuan to 8.7 billion yuan, and it is expected to exceed 9.5 billion yuan in 2019. At present, there is only one generic drug company producing and selling milnacipran hydrochloride in the domestic market. In 2018, China's domestic sales were 42.63 million yuan.

Hot Tags: milnacipran hydrochloride api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Bemeprost API, Vardenafil API, Tetrabenazine API, Edoxaban API, Perindopril Tert butylamine Salt API, Brinzolamide API

• Previous: Tazarotene API
• Next: Doxazosin Mesylate API